FINEOS Achieves Unprecedented Client Go Live Success in 2020
28.1.2021 17:15:00 EET | Business Wire | Press release
FINEOS Corporation (ASX:FCL) continues to demonstrate its long standing purpose to “help our clients care for the people they serve through the delivery of superior insurance technology” in 2020 with the completion of 8 new installations and 7 major upgrades of the FINEOS Platform. As a leading provider of core systems for life, accident and health insurers globally, FINEOS offers unparalleled core solutions that help carriers become more dynamic, scalable and competitive.
“We are pleased with our performance over the past year, especially given the challenges we all face in these times of COVID,” said Michael Kelly, CEO of FINEOS. “Many of our global clients are actively engaged in brand-new installations, version upgrades and platform migrations. This tells us that our clients see the value of our significant R&D investment made over the past 5 years and indeed are modernizing their core systems in support of their digital transformation. We are grateful to our clients and SI partners for the tremendous implementation and upgrade achievements over the past year.”
By upgrading to the SaaS-based FINEOS Platform, clients will reap the benefits of a more modern and comprehensive unified system for integrated absence, group and voluntary benefits.
“The FINEOS Platform is purpose built to support the Employee Benefits market and therefore provides several advantages to our clients over repurposed P&C core systems,” said Chuck Johnston, CMO of FINEOS. “As a result, our clients enjoy easier installations and upgrades. What’s more, innate policy and customer management capabilities that exist across the entire FINEOS Platform provide consistent product information as well as powerful, frictionless process and workflows across the platform. These foundational capabilities are distinctive to the FINEOS Platform market offerings from claims to Integrated Disability and Absence Management (IDAM) to the full FINEOS AdminSuite which enables clients to move to quote to claim on one system.”
Demonstrated client success metrics include:
- 40% improvement in staff satisfaction in billing and policy admin
- 27% reduction in disability duration
- 10% increase in client on-time contact
- 25% increase in claim settlements per day
- 12% improvement in RTW (Return to Work)
- 93% reduction for claims acceptance time: now accepted within five days of an accident, down from seventy
Since the start of the COVID-19 pandemic, Employee Benefits carriers in North America and protection schemes across the globe have seen increased demand from their customers for new products, remote functionality, and faster processing times that cannot be achieved with legacy systems.
The value of the FINEOS Platform with excellent client support is evident in the company’s long-term partnerships. “Our partnership with FINEOS continues to grow and we are realizing benefits from the FINEOS system, including streamlined processes which enable our managers to focus on providing excellent outcomes to QSuper members,” said Phil Frazer, CEO of QInsure, Australia. “We are excited to continue our partnership with FINEOS to help support our organization’s agility, digital customer experience and our service excellence.”
In North America, where claims and paid leave laws continue to reverberate with change due to COVID, the necessity for carriers to embrace Integrated Disability and Absence Management (IDAM) remains a critical path to future success. Throughout 2020, FINEOS continued to focus on integrated absence management as a core capability, helping carriers simplify the complex process of managing absence to improve engagement and user experience. As the industry leader for core software, FINEOS plans to raise the industry standard in 2021 even further by continually expanding the FINEOS Platform for Employee Benefits.
“Insurers need technology solutions to meet the increased expectations for customer experience and to increase efficiencies and outcomes for key products like Disability and Absence Management,” says Nancy Casbarro, Vice President of Research and Consulting at Novarica. “They’re looking to solution providers like FINEOS for solutions that offer digital solutions for self-service, configurable policy administration, enrollment and claims capabilities all driving greater efficiency, reliable upgrades and long-term system lifecycle support.”
About FINEOS Corporation
FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest group life and health carriers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive insurers in North America, Europe, and Asia Pacific.
The FINEOS Platform provides core administration capabilities including absence management, billing, claims, payments, policy administration, provider management and new business and underwriting; all of which are configurable to operate independently or as FINEOS AdminSuite, an end-to-end core administration suite.
For more information, visit www.FINEOS.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005062/en/
Contact information
Victoria Jamison
Marketing Manager
FINEOS Corporation
+ 353 1 639 9700
victoria.jamison@FINEOS.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
